PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
GeneDx Holdings Corp. (WGS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

Sector

Healthcare

IPO Date

Nov 4, 2020

Highlights

Market Cap

$3.06B

EPS (TTM)

-$1.94

Total Revenue (TTM)

$305.45M

Gross Profit (TTM)

$185.56M

EBITDA (TTM)

-$30.07M

Year Range

$7.16 - $115.60

Target Price

$107.33

Short %

20.50%

Short Ratio

2.54

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
WGS vs. ASM WGS vs. ENR.DE WGS vs. VST WGS vs. LLY WGS vs. UPRO WGS vs. SPY WGS vs. VIPS WGS vs. ^GSPC WGS vs. SEZL WGS vs. APP
Popular comparisons:
WGS vs. ASM WGS vs. ENR.DE WGS vs. VST WGS vs. LLY WGS vs. UPRO WGS vs. SPY WGS vs. VIPS WGS vs. ^GSPC WGS vs. SEZL WGS vs. APP

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in GeneDx Holdings Corp., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%50.00%100.00%150.00%200.00%SeptemberOctoberNovemberDecember2025February
198.57%
9.82%
WGS (GeneDx Holdings Corp.)
Benchmark (^GSPC)

Returns By Period

GeneDx Holdings Corp. had a return of 32.16% year-to-date (YTD) and 1,361.58% in the last 12 months.


WGS

YTD

32.16%

1M

36.61%

6M

198.59%

1Y

1,361.58%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

4.01%

1M

1.13%

6M

9.82%

1Y

22.80%

5Y*

12.93%

10Y*

11.26%

*Annualized

Monthly Returns

The table below presents the monthly returns of WGS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-2.62%32.16%
202440.00%111.69%12.02%86.97%14.88%33.30%25.17%-2.38%32.87%92.48%-4.04%-1.95%2,694.91%
202360.98%17.65%-27.00%-24.93%-16.83%-20.74%24.33%-39.95%-18.20%-48.90%-5.91%57.14%-68.43%
2022-23.32%2.05%-12.03%-29.97%-5.12%-38.24%28.57%-37.04%-13.92%17.31%-59.81%-36.23%-94.08%
202113.32%59.95%-25.59%-9.00%-6.57%10.66%-19.49%-15.78%-20.11%6.32%-17.35%-33.13%-59.60%
20204.54%7.76%12.65%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 99, WGS is among the top 1% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of WGS is 9999
Overall Rank
The Sharpe Ratio Rank of WGS is 100100
Sharpe Ratio Rank
The Sortino Ratio Rank of WGS is 9999
Sortino Ratio Rank
The Omega Ratio Rank of WGS is 9898
Omega Ratio Rank
The Calmar Ratio Rank of WGS is 100100
Calmar Ratio Rank
The Martin Ratio Rank of WGS is 100100
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for GeneDx Holdings Corp. (WGS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for WGS, currently valued at 14.95, compared to the broader market-2.000.002.0014.951.74
The chart of Sortino ratio for WGS, currently valued at 7.02, compared to the broader market-4.00-2.000.002.004.006.007.022.36
The chart of Omega ratio for WGS, currently valued at 1.86, compared to the broader market0.501.001.502.001.861.32
The chart of Calmar ratio for WGS, currently valued at 19.23, compared to the broader market0.002.004.006.0019.232.62
The chart of Martin ratio for WGS, currently valued at 155.05, compared to the broader market-10.000.0010.0020.0030.00155.0510.69
WGS
^GSPC

The current GeneDx Holdings Corp. Sharpe ratio is 14.95. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of GeneDx Holdings Corp. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio0.0010.0020.0030.0040.0050.00SeptemberOctoberNovemberDecember2025February
14.95
1.74
WGS (GeneDx Holdings Corp.)
Benchmark (^GSPC)

Dividends

Dividend History


GeneDx Holdings Corp. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-88.07%
-0.43%
WGS (GeneDx Holdings Corp.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the GeneDx Holdings Corp.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the GeneDx Holdings Corp. was 99.85%, occurring on Nov 13, 2023. The portfolio has not yet recovered.

The current GeneDx Holdings Corp. drawdown is 88.07%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.85%Feb 16, 2021692Nov 13, 2023
-7.25%Dec 28, 20205Jan 4, 20216Jan 12, 202111
-4.43%Jan 14, 20213Jan 19, 20213Jan 22, 20216
-4.37%Dec 3, 20201Dec 3, 20207Dec 14, 20208
-4.01%Jan 27, 20211Jan 27, 20214Feb 2, 20215

Volatility

Volatility Chart

The current GeneDx Holdings Corp. volatility is 47.64%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%SeptemberOctoberNovemberDecember2025February
47.64%
3.01%
WGS (GeneDx Holdings Corp.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of GeneDx Holdings Corp. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for GeneDx Holdings Corp..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab